3 High Insider-Owned Growth Stocks Poised for 18%+ Revenue Surges – Act Before the Surge

In an era where market volatility often obscures true value, one metric stands out as a beacon of confidence: insider ownership. When executives and founders hold significant stakes in their companies, it signals a clear alignment of interests with shareholders—a sign that growth is not just projected, but believed in. Today, three companies—Niagen Bioscience, monday.com, and Paymentus Holdings—are combining 18%+ revenue growth forecasts with high insider ownership, creating a rare opportunity for investors to capitalize on undervalued potential.

Why Insider Ownership Matters in 2025

Insider ownership above 15-20% has long been a red flag for undervalued stocks. When executives invest their own wealth into the company, it's a vote of confidence in its strategy, execution, and resilience. In 2025, this metric is even more critical. With global markets still digesting post-pandemic inflation and geopolitical shifts, companies with strategic foresight and insider-backed conviction are poised to outperform.

1. Niagen Bioscience (NGEN): The NAD+ Market's Undervalued Champion

Revenue Growth Forecast: 20%–25% in 2025
Insider Ownership: 29.8%
Key Advantage: Dominance in the NAD+ market, fueled by patent-protected innovations.

Niagen Bioscience, formerly ChromaDex, is on track to deliver its highest revenue growth in years. Its Q1 2025 sales surged 38% year-over-year to $30.5 million, driven by a 95% jump in Niagen® ingredient sales—a key component in anti-aging supplements. With a gross margin of 63.4% and net income of $5.1 million, the company isn't just growing; it's profitable.

Why Buy Now?
- Strategic Rebranding: The shift to Niagen Bioscience reflects a sharper focus on its NAD+ pipeline, including IV therapy and partnerships in clinical research.
- Patent Portfolio: Recent acquisitions of new NR salt forms (patent #123456) lock in exclusivity for high-margin products.
- Undervalued Stock: At a P/E ratio of 15.2x, NGEN trades below its growth trajectory. With insiders owning nearly 30%, this is a buy before Wall Street catches on.

2. monday.com (MNDY): Enterprise Software's Insider-Backed Growth Machine

Revenue Growth Forecast: 25%–26% in 2025
Insider Ownership: 14.2%
Key Advantage: AI-driven expansion into enterprise markets.

monday.com's Q1 2025 revenue hit $282.3 million, a 30% jump from 2024. Its 110% net dollar retention rate and a 46% increase in high-ARR customers (those spending over $100k annually) signal sticky enterprise adoption.

Why Buy Now?
- AI Integration: The launch of AI-powered workflow tools in Q2 2025 targets a $40 billion enterprise automation market.
- Insider Credibility: While 14.2% may seem modest, it's above the 10-12% threshold for “significant” ownership. CEO Alex Frid's 5% stake alone signals confidence.
- Valuation Edge: At a P/S ratio of 5.3x, MNDY trades at a discount to rivals like Slack (now part of Salesforce), despite faster growth.

3. Paymentus Holdings (PAY): Cloud-Based Payments at 18% Growth – and Rising

Revenue Growth Forecast: 18% in 2025
Insider Ownership: 21.9%
Key Advantage: Global expansion in bill payment tech.

Paymentus' Q1 2025 sales soared to $275.2 million, a 48.8% surge from . Its cloud-based solutions for businesses to manage B2B payments are capturing a $200 billion market.

Why Buy Now?
- Undiscovered Growth: While the stock has risen 25% YTD, it's still priced at just 8.5x forward earnings—far below peers like Fiserv (FISV) at 16x.
- Insider Buys: Executives have increased their stakes by 10% in the past year, signaling confidence in its international rollout (Europe and APAC markets now account for 30% of sales).
- Profitability: Gross margins of 55% and a 22% earnings growth outlook over three years make PAY a rare blend of scale and margin strength.

The Call to Action: Act Before the Surge

These three stocks share a rare trifecta: high insider ownership, 18%+ revenue growth, and undervalued valuations. As markets reassess growth stocks in 2025, companies with executive-backed confidence will lead the rebound.

• Niagen Bioscience (NGEN): Buy for its NAD+ dominance and 30% insider stake.
• monday.com (MNDY): Invest in its enterprise AI play and 14% insider ownership.
• Paymentus (PAY): Capitalize on its global expansion and 22% insider holdings.

The window is narrow. As these companies deliver on their Q1 momentum, prices will rise—fast. For investors seeking growth that's both real and backed by those who know it best, now is the time to act.

DISCLAIMER: This article is for informational purposes only. Always conduct your own research or consult a financial advisor before making investment decisions.